PRTC - NASDAQ
PureTech Health plc
$17.84
-0.94%PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and psychosis in Alzheimer's disease; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; an immunomodulation platform to treat chronic and acute inflammatory disorders; oral therapies based on defined consortia of bacteria is isolated from the human microbiome; and therapies to treat cognitive dysfunction associated with depression, multiple sclerosis, post COVID and ICU, and cancer related conditions. It also provides hematopoietic stem cell based therapies for patients with blood cancer; a voice-based technology platform to detect voice changes linked to health conditions; and a technology platform for the oral delivery of biologics, vaccines, and other drugs. In addition, the company is developing LYT-100 to treat lymphedema, and other lymphatic flow disorders; LYT-200, a IgG4 monoclonal antibody to target galectin-9; LYT-210 to treat solid tumors; Glyph, a synthetic lymphatic targeting chemistry platform; Orasome technology to enable the oral administration of macromolecule therapeutic payloads; meningeal lymphatics platform to treat Alzheimer's and Parkinson's diseases; and Alivio technology platform for inflammation-targeted disease immunomodulation. PureTech Health plc has collaboration and license agreements with Boehringer Ingelheim International GMBH; Eli Lilly and Company; Imbrium Therapeutics L.P.; and Shionogi & Co., Ltd. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
At a Glance
Live SnapshotPureTech Health plc Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
PureTech Health plc Income Statement
PRTC • NASDAQ
| PureTech Health plc Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||
4.7M | 4.8M | 3.3M | 2.1M | 10M | 8.3M | 8.7M | 16.4M | 650K | 4.4M | 11.7M | 2M | 7M | 7.9M | |
GROSS PROFIT | ||||||||||||||
(0.0) | (0.0) | (4.9M) | (152.4M) | (110.5M) | (0.0) | (85.8M) | (77.4M) | (71M) | (1.6M) | (740K) | (0.0) | (0.0) | (0.0) | |
4.7M | 1.3M | -1.6M | -136.8M | -100.5M | 8.3M | -77.2M | -61M | -70.4M | 2.9M | 11M | 2M | 7M | 7.9M | |
OPERATING INCOME | ||||||||||||||
(103.2M) | (140.4M) | (54.6M) | (61M) | (160.3M) | (127.9M) | (144.1M) | (120.4M) | (116.1M) | (78.4M) | (55.4M) | (19.5M) | (10.1M) | (14M) | |
(20.7M) | (27.5M) | (48.4M) | (35.7M) | (30.8M) | (26.5M) | (34.9M) | (24.4M) | (46.3M) | (37.2M) | (18.4M) | (7.2M) | (3.6M) | (3.8M) | |
(45.7M) | (54.3M) | (96.2M) | (116.1M) | (81.5M) | (61.2M) | (65.2M) | (57.3M) | (71.7M) | (41.2M) | (13.4M) | (2.8M) | (2.8M) | (4.2M) | |
-98.5M | -136.1M | -146.2M | -197.8M | -150.3M | -119.5M | -135.4M | -104M | -115.4M | -73.9M | -43.6M | -17.4M | -3.7M | -9.4M | |
PRE-TAX INCOME | ||||||||||||||
(45.8M) | (10M) | (13.5M) | (4M) | (4.7M) | (2.9M) | (4.1M) | (14.8M) | (10.2M) | (6.8M) | (4.4M) | (2.6M) | (367K) | (609K) | |
-32.7M | 12.6M | 2.5M | 1.8M | -4.5M | -1.8M | 260K | -11.4M | -8.5M | -5.6M | -4.1M | -2.5M | -331K | -579K | |
(36.8M) | (58.6M) | -90M | -90.8M | (48M) | (40.2M) | (44M) | -278K | (14K) | (46K) | (448K) | (0.0) | (0.0) | (0.0) | |
-12.4M | 159.9M | 110.1M | 105M | 91.3M | 138.5M | 613.9M | 35.6M | 44.7M | -9.3M | -12.7M | -58.8M | -1.6M | -4.7M | |
-110.9M | 23.8M | -36.1M | -92.8M | -59M | 19M | 478.5M | -68.4M | -70.7M | -83.2M | -56.3M | -76.2M | -5.3M | -10.8M | |
NET INCOME | ||||||||||||||
-842K | -4M | (30.5M) | -55.7M | (3.8M) | (14.4M) | (112.4M) | (2.2M) | -14K | -1.6M | (1.9M) | -278K | (274K) | (535K) | |
-109.7M | 53.5M | -65.7M | -50.4M | -60.6M | 6M | 421.1M | -43.7M | 30.9M | -48.8M | -39.4M | -41.6M | -4.3M | -11.1M |
SEC Filings
PRTC - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
6-K 6-K 2026 Q2 Q2 | May 01, 2026 | May 01, 2026 | 2026 | |
6-K 6-K 2026 Q2 Q2 | April 29, 2026 | April 29, 2026 | 2026 | |
20-F 20-F 2025 FY FY | April 29, 2026 | December 31, 2025 | 2025 | |
6-K 6-K 2026 Q2 Q2 | April 29, 2026 | April 29, 2026 | 2026 | |
6-K 6-K 2025 Q4 Q4 | December 18, 2025 | December 18, 2025 | 2025 | |
6-K 6-K 2025 Q4 Q4 | December 10, 2025 | December 10, 2025 | 2025 | |
6-K 6-K 2025 Q2 Q2 | August 28, 2025 | June 30, 2025 | 2025 | |
6-K 6-K 2025 Q3 Q3 | July 16, 2025 | July 16, 2025 | 2025 | |
6-K 6-K 2025 Q3 Q3 | July 08, 2025 | July 08, 2025 | 2025 | |
6-K 6-K 2025 Q2 Q2 | June 16, 2025 | June 16, 2025 | 2025 |
Related Guides
Continue your PRTC research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.